Abstract
Atherosclerosis is a multifactorial and long-lasting process in humans. Therefore, animal models where more rapid changes occur can be useful for the study of this process. Among such models are the apolipoprotein (apo) E knock out mice. Apo E deficient mice show impaired clearing of plasma lipoproteins and they develop atherosclerosis in a short time. The current review considers lipid metabolism and inflammation as well as nutritional and pharmacological agents affecting atherosclerosis, using the apo E knock out mouse model.
Keywords: Apolipoprotein E, knock out, atherosclerosis
Current Pharmaceutical Design
Title: Apolipoprotein E Knockout Models
Volume: 14 Issue: 4
Author(s): Genovefa Kolovou, Katherine Anagnostopoulou, Dimitri P. Mikhailidis and Dennis V. Cokkinos
Affiliation:
Keywords: Apolipoprotein E, knock out, atherosclerosis
Abstract: Atherosclerosis is a multifactorial and long-lasting process in humans. Therefore, animal models where more rapid changes occur can be useful for the study of this process. Among such models are the apolipoprotein (apo) E knock out mice. Apo E deficient mice show impaired clearing of plasma lipoproteins and they develop atherosclerosis in a short time. The current review considers lipid metabolism and inflammation as well as nutritional and pharmacological agents affecting atherosclerosis, using the apo E knock out mouse model.
Export Options
About this article
Cite this article as:
Kolovou Genovefa, Anagnostopoulou Katherine, Mikhailidis P. Dimitri and Cokkinos V. Dennis, Apolipoprotein E Knockout Models, Current Pharmaceutical Design 2008; 14 (4) . https://dx.doi.org/10.2174/138161208783497769
DOI https://dx.doi.org/10.2174/138161208783497769 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chymase Inhibitors
Current Pharmaceutical Design From Protein-Protein Interactions to Rational Drug Design: Are Computational Methods Up to the Challenge?
Current Topics in Medicinal Chemistry Chagas Disease: Progress and New Perspectives
Current Medicinal Chemistry Successfully Resuscitated Sudden Cardiac Death in a Young Homosexual Male with HIV Myocarditis
Current HIV Research Management of Peyronie's Disease after Collagenase (Xiaflex:<sup>®</sup>)
Current Drug Targets Editorial (Thematic Issues: New Developments in the Medicinal Chemistry of Some Azoles)
Current Topics in Medicinal Chemistry Targeting Metabolic Enzymes in Cancer – Clinical Trials Update
Current Enzyme Inhibition Premature Ageing Prevention: Limitations and Perspectives of Pharmacological Interventions
Current Drug Targets Keeping the Balance Between Proliferation and Differentiation:The Primary Cilium
Current Genomics Bacterial Urease and its Role in Long-Lasting Human Diseases
Current Protein & Peptide Science Non Enzymatic Glycated Proteins in the Blood and Cardiovascular Disease
Current Pharmaceutical Design Angina in Women without Obstructive Coronary Artery Disease
Current Cardiology Reviews Mst1: Function and Mechanism in Brain and Myocardial Ischemia Reperfusion Injury
Current Neuropharmacology Resuscitation of the Patient with the Functionally Univentricular Heart
Current Pediatric Reviews Why is the Incidence of Type 1 Diabetes Increasing?
Current Diabetes Reviews Sodium Intake Recommendations: A Subject that Needs to be Reconsidered
Current Hypertension Reviews Anti-TNF Treatment in Rheumatoid Arthritis
Current Pharmaceutical Design Nanotechnology and Antioxidant Therapy: An Emerging Approach for Neurodegenerative Diseases
Current Medicinal Chemistry The Coronary Circulation in Cyanotic Congenital Heart Disease
Current Cardiology Reviews New Insights into HLA-G and Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued)